PTGX - Protagonist Therapeutics, Inc.
About Protagonist Therapeutics, Inc. (https://www.protagonist-inc.com)
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Dinesh V. Patel | Chief Executive Officer, President, Secretary & Director | 1957 | $1,414,292 USD |
| Arturo Molina FACP | Chief Medical Officer | 1959 | $949,992 USD |
| Asif Ali | Executive Vice President & Chief Financial Officer | 1974 | $826,242 USD |
| Abha Bommireddi | Executive Vice President & Chief of Staff | – | – |
| Ashok Bhandari | EVP & Chief Discovery Officer | 1964 | – |
| Carena Spivey | Executive VP & Chief Human Resources Officer | – | – |
| Carter J. King | Executive Vice President of Business Development | 1971 | – |
| Matthew Gosling | Executive Vice President and Chief Legal & Business Officer | 1971 | – |
| Newman Yeilding | Executive Vice President, Chief Scientific Officer | – | – |
| Venkat Thalladi | EVP & Chief Technical Officer | – | – |